Is Edwards Lifesciences Corporation (EW) a Buy, Sell, or Hold?
Edwards Lifesciences Corporation
NYSE:EW
$90.09 USD
-$1.7 (-1.85%)
- Volume
- 5.25M
- Average Volume
- 5.15M
- Market Capitalization
- $51.87B
- P/E Ratio
- 47.67
- Dividend Yield
- 0.00%
- Price Target
- $100.00
- Year High
- $96.29
- Year Low
- $72.30
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $4.42
Industry, Sector & symbol
| Stock Exchange | NYSE |
| CEO | Bernard J. Zovighian |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Current Symbol | EW |
| CUSIP | 28176E108 |
| CIK | 0001099800 |
| Web | https://www.edwards.com |
| Phone | 949 250 2500 |
| Currency | USD |
| Employees | 16000 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.07 |
| Payout Ratio | 0.00 |
| Current Ratio | 4.42 |
| Quick Ratio | 3.63 |
| Cash Ratio | 1.74 |
Sales & Book Value
| Annual Sales | $6.07B |
| Price / Sales | 8.23 |
| Cash Flow | 1.88 |
| Price / Cash Flow | 47.61 |
| Price / Book | 5.05 |
Price Target and Rating
| Average Stock Price Forecast | $100.00 |
| High Stock Price Forecast | $110.00 |
| Low Stock Price Forecast | $85.00 |
| Forecast Upside/Downside | -9.91% |
| Consensus Rating | Neutral |
| Rating Score(0-5) | 3 |
| Research Coverage | 48 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.83 |
| Trailing P/E Ratio | 47.67 |
| PEG Ratio | -0.65 |
| P/E Growth | -0.65 |
| Net Income | $1.07B |
| Net Margin | 17.34% |
| Pretax Margin | 20.59% |
| Return on Equity | 10.55% |
| Return on Assets | 8.20% |
Financials Score
| AltmanZ Score | 13.15 |
| Piotroski Score | 6.00 |
| Working Capital | 4.82B |
| Total Assets | 13.32B |
| Ebit | 1.26B |
| Market Cap | 51.87B |
| Total Liabilities | 2.99B |
Poll Results
About Edwards Lifesciences Corporation (NYSE:EW) Stock
Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, ... the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
2026-07-03 12:34:00
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.
2026-06-26 10:15:00
NEW YORK--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new data presented at New York Valves 2026, the annual conference organized by the Cardiovascular Research Foundation, which reinforce the company's leadership in advancing high-quality scientific evidence and innovating for patients. These new data – spanning aortic, mitral and tricuspid therapies – provide further understanding of the complexity of structural heart disease and the need for innovative treatment options.
2026-06-22 07:01:00
EL SEGUNDO, Calif.--(BUSINESS WIRE)--Pacific Defense today announced the launch of the SWH1530VP, a next-generation dual-enclave 100/40 Gigabit Ethernet switch engineered to provide secure, deterministic, and high-performance networking for modern Command, Control, Communications, Computers, Cyber, Intelligence, Surveillance, Reconnaissance (C5ISR), Electronic Warfare (EW), and edge computing applications. Aligned with SOSA™, CMOSS, and OpenVPX™ standards, the 3U VPX module combines advanced La.
EW DCF Analysis: Intrinsic Value $51 vs Price $89
2026-06-17 07:27:00
On June 17, 2026, we present a DCF analysis for Edwards Lifesciences Corp (EW). The company has shown a price performance of +1.2% over the past week, +8.8% ove
Edwards Lifesciences Stands Out As US Agency Eyes Broader Access For Heart Valve Device
2026-06-16 13:52:47
On Monday, the Centers for Medicare & Medicaid Services (CMS) proposed removing the coverage with evidence development (CED) requirement for Transcatheter Aortic Valve Replacement (TAVR) in patients with symptomatic severe aortic stenosis.
Should You Continue to Hold EW Stock in Your Portfolio?
2026-06-12 09:36:14
Edwards gains from strong TMTT growth, RESILIA adoption and expanding TAVR use, but macro pressures and currency swings remain key risks.
East West Announces $858,000 Non-Brokered Private Placement
2026-06-12 08:00:00
Vancouver, British Columbia--(Newsfile Corp. - June 12, 2026) - East West Minerals Ltd. (TSXV: EW) ("East West" or the "Company") announces that further to a price reservation filed on June 10, 2026, the Company has arranged a non-brokered private placement financing (the "Financing") of up to 7,800,000 units (each a "Unit"), at a price of $0.11 per Unit, to raise up to $858,000.
Edwards Lifesciences Corp (EW) Stock Up 3.1% and Still Undervalued -- GF Score: 95/100
2026-05-22 17:20:00
On May 22, 2026, Edwards Lifesciences Corp (EW) shares rose 3.1% to a current price of $85.78. The stock has fluctuated between $72.30 and $87.89 over the past
Frequently Asked Questions
-
What is the current Edwards Lifesciences Corporation (EW) stock price?
-
Edwards Lifesciences Corporation(NYSE:EW) stock price is $90.09 in the last trading session. During the trading session, EW stock reached the peak price of $96.29 while $72.3 was the lowest point it dropped to. The percentage change in EW stock occurred in the recent session was --1.85% while the dollar amount for the price change in EW stock was -$-1.7.
-
EW's industry and sector of operation?
-
The NYSE listed EW is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of EW?
-
Daveen Chopra | Corporate Vice President of Transcatheter Mitral & Tricuspid Therapies
Donald E. Bobo Jr. | Corporate Vice President of Strategy & Corporate Development
Joseph Nuzzolese | Corporate Vice President of Global Operations & Quality
Mark D. Peterson | Corporate Vice President & General Counsel
Wayne T. Markowitz | GM & Senior VP of Surgical Structural Heart -
How many employees does EW have?
-
Number of EW employees currently stands at 16000. EW operates from One Edwards Way, Irvine, CA 92614, US.
-
Link for EW official website?
-
Official Website of EW is: https://www.edwards.com
-
How do I contact EW?
-
EW could be contacted at phone #949 250 2500 and can also be accessed through its website. EW operates from One Edwards Way, Irvine, CA 92614, US.
-
How many shares of EW are traded daily?
-
The average number of EW shares traded daily for last 3 months was 5.15M.
-
What is the market cap of EW currently?
-
The market value of EW currently stands at $51.87B with its latest stock price at $90.09